Commentary: Biomedical innovation in the era of health care spending constraints

Health Affairs

Volumn 34, Issue 2, 2015, Pages 203-209

  Robinson, James C ^a  

^a School of Public Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCOUNTABLE CARE ORGANIZATION; BIOMEDICAL TECHNOLOGY ASSESSMENT; BIOMEDICINE; COMPETITION; COST EFFECTIVENESS ANALYSIS; DRUG INDUSTRY; HEALTH CARE COST; HEALTH CARE INDUSTRY; HEALTH CARE POLICY; HOSPITAL FINANCE; HOSPITAL PURCHASING; HUMAN; MARKET; MEDICAID; MEDICAL DEVICE; MEDICAL TECHNOLOGY; MEDICARE; NOTE; PHARMACY AND THERAPEUTICS COMMITTEE; PRODUCT DEVELOPMENT; REIMBURSEMENT; COST CONTROL; DEVICES; ECONOMIC ASPECT; ECONOMICS; HEALTH INSURANCE; MEDICAL RESEARCH; ORGANIZATION; PROCEDURES; PURCHASING; STANDARDS; TRENDS;

BIOSIMILAR AGENT;

BIOMEDICAL RESEARCH; BIOMEDICAL TECHNOLOGY; BIOSIMILAR PHARMACEUTICALS; COST CONTROL; DECISION MAKING, ORGANIZATIONAL; DRUG INDUSTRY; ECONOMIC COMPETITION; EQUIPMENT AND SUPPLIES; HEALTH CARE SECTOR; HUMANS; INSURANCE, HEALTH; VALUE-BASED PURCHASING;

EID: 84922692785     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2014.0975     Document Type: Note

References (36)

1. Congressional Budget Office. Technological change and the growth of health care spending. Washington (DC): CBO; 2008.
2. Chandra A, Skinner J. Technology growth and expenditure growth in health care. J Econ Lit. 2012;50(3): 645-80.
3. Robinson JC. Purchasing medical innovation: the right technology, for the right patient, at the right price. Oakland (CA): University of California Press; forthcoming 2015.
4. Chilukuri S, Gordon M, Musso C, Ramaswamy S. Design to value in medical devices [Internet]. Washington (DC): McKinsey and Company; 2010 [cited 2014 Dec 19]. Available from: http://www.mckinsey.com/~/media/mckinsey/dotcom/client_service/pharma%20and%20medical%20products/pmp%20new/pdfs/774172_design_to_value_in_medical_devices1.ashx
5. Narayanan A, Padhi A, Williams J. Designing products for value [Internet]. Washington (DC): McKinsey and Company; 2012 [cited 2014 Dec 5]. Available from: http://www .mckinsey.com/insights/innovation/designing_products_for_value
6. Christensen CM. The innovator's dilemma: when new technologies cause great firms to fail. Boston (MA): Harvard Business School Press; 1997.
7. Timmons H. GE chief sees India helping cut costs of US health care. New York Times. 2009 Oct 3; Sect. B:3.
8. Food and Drug Administration. Facts about generic drugs [Internet]. Washington (DC): FDA; 2012 Sep 19 [cited 2014 Dec 9]. Available from: http://www.fda.gov/drugs/resourcesforyou/consumers/buyingusingmedicinesafely/understandinggenericdrugs/ucm167991.htm
9. Singer N. Drug firms apply brand to generics. New York Times. 2010 Feb 16;Sect. B:1.
10. Spatz I, McGee N. Health policy briefs: specialty pharmaceuticals [serial on the Internet]. 2013 Nov 25 [cited 2014 Dec 9]. Available from: http://www.healthaffairs.org/healthpolicybriefs/brief.php?brief_id=103
11. Megerlin F, Lopert R, Taymor K, Trouvin JH. Biosimilars and the European experience: implications for the United States. Health Aff (Millwood). 2013;32(10):1803-10.
12. Bourgoin AF, Nuskey B. An outlook on US biosimilar competition. Philadelphia (PA): Thomson Reuters; 2013 Apr.
13. Barei F, Le Pen C, Simoens S. The generic pharmaceutical industry: moving beyond incremental innovation towards re-innovation. GaBI J. 2013;2(1):13-9.
14. Neumann PJ.Why don't Americans use cost-effectiveness analysis? Am J Manag Care. 2004;10(5):308-12.
15. Mohr P. Looking at CER from Medicare's perspective. J Manag Care Pharm. 2012;18(4 Suppl A):S5-8.
16. Pearson SD, Bach PB. How Medicare could use comparative effectiveness research in deciding on new coverage and reimbursement. Health Aff (Millwood). 2010;29(10):1796-804.
17. Sullivan SD, Lyles A, Luce B, Grigar J. AMCP guidance for submission of clinical and economic evaluation data to support formulary listing in US health plans and pharmacy ben-efits management organizations. J Manag Care Pharm. 2001;7(4): 272-82.
18. Spooner JJ, Gandhi PK, Connelly SB. AMCP format dossier requests: manufacturer response and formulary implications for one large health plan. J Manag Care Pharm. 2007; 13(1):37-43.
19. Health Care Industry Committee. Navigating the new era of technology assessment: strategies and tools for working with value analysis, capital budgeting, and technology assessment companies. Washington (DC): Advisory Board Company; 2010 Apr.
20. Gutowski C, Maa J, Hoo KS, Bozic KJ. Health technology assessment at the University of California-San Francisco. J Healthc Manag. 2011; 56(1):15-29.
21. Pearson SD, Bach PB. How Medicare could use comparative effectiveness research in deciding on new coverage and reimbursement. Health Aff (Millwood). 2010;29(10):1796-804.
22. Palmer E. The 10 best-selling drugs of 2013 [Internet]. Thousand Oaks (CA): Fierce Pharma; 2014 Mar 25 [cited 2014 Dec 10]. Available from: http://www.fiercepharma.com/special-reports/10-best-sellingdrugs-2013
23. Dautel N, Haren M, Bluestein K, Sadiwnyk K. Prior authorization tracking tool for rheumatoid arthritis: trends in the marketplace, second quarter 2011. San Francisco (CA): Zitter Group; 2011. (Report in author's possession; not publicly available.)
24. Long G, Mortimer R, Sanzenbacher G. Recent average price trends for implantable medical devices, 2007-2011 [Internet]. Washington (DC): Analysis Group; 2013 Sep [cited 2014 Dec 10]. Available from: http://advamed.org/res.download/365
25. Robinson JC. Case studies of orthopedic surgery in California: the virtues of care coordination versus specialization. Health Aff (Millwood). 2013;32(5):921-8.
26. Montgomery K, Schneller ES. Hospitals' strategies for orchestrating selection of physician preference items. Milbank Q. 2007;85(2): 307-35.
27. Ketcham JD, Furukawa MF. Hospital-physician gainsharing in cardiology. Health Aff (Millwood). 2008;27(3):803-12.
28. Arnold and Porter LLP. Final rule issued for physician payment sunshine provisions of the Affordable Care Act [Internet]. Washington (DC): Arnold and Porter LLP; 2013 Feb [cited 2014 Dec 10]. Available from: http://www.arnoldporter .com/resources/documents/Advisory%20Final_Rule_Issued_for_Physician_Payment_Sunshine_Provisions_Affordable_Care_Act .pdf
29. An interesting case study of orthopedic process improvements at a major Philadelphia hospital is provided in Bohmer RMJ, Huckman RS, Weber J, Bozic KJ. Managing orthopaedics at Rittenhouse Medical Center. Cambridge (MA): Harvard Business School Case 607-152; 2007 (revised 2010).
30. Loftus P. Senate committee is investigating pricing of hepatitis C drug. Wall Street Journal. 2014 Jul 11.
31. Liu S, Watcha D, Holodniy M, Goldhaber-Fiebert JD. Sofosbuvirbased treatment regiments for chronic, genotype 1 hepatitis C virus infection in US incarcerated populations: a cost-effectiveness analysis. Ann Intern Med. 2014;161(8): 546-53.
32. Rockoff JD. Once-a-day hepatitis pill approved. Wall Street Journal. 2014 Oct 11.
33. Loftus P. Lucrative drug niche sparks legal scramble. Wall Street Journal. 2014 Jul 20.
34. Hanson K, Bondurant E. Cancer insurance mandates and exceptions. Denver (CO): National Conference of State Legislatures; 2009.
35. Centers for Medicare and Medicaid Services. Medicare prescription drug benefit manual [Internet]. Baltimore (MD): CMS; 2010. Chapter 6, Part D drugs and formulary requirements; [cited 2014 Dec 10]. Available from: https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/downloads/Chapter6.pdf
36. Zenios S, Makower J, Yock P, Brinton TJ, Kumar UN, Denend L, et al. Biodesign: the process of innovating medical technologies. Cambridge: Cambridge University Press; 2009.